查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2098929

口服避孕藥市場－2026-2032年全球市場預測

Oral Contraceptive Pills Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，口服避孕藥市場規模將達到 317.7 億美元，複合年成長率為 7.09%。

主要市場統計數據
基準年 2025 196.6億美元
預計年份：2026年 210.5億美元
預測年份 2032 317.7億美元
複合年成長率 (%) 7.09%

口服避孕藥仍然是最廣泛使用的可逆避孕方法之一，這得益於數十年的臨床證據、不斷擴展的生殖健康項目以及使用者對主導計劃生育的持續需求。這類藥物包括含有雌激素和黃體素的複方口服避孕藥以及僅含黃體素的口服避孕藥，每種藥物都針對不同的臨床需求，例如年齡、哺乳狀況、心血管風險、偏頭痛史、藥物交互作用以及患者偏好等因素。女性醫療保健服務可及性的提高、數位醫療的興起、公共部門採購、關於非處方藥（OTC）供應的討論以及人們對月經週期管理、痤瘡治療、子宮卵巢症相關症狀控制和多囊性卵巢症候群（PCOS）支持等需求的日益重視，都推動了口服避孕藥的需求成長。同時，行業相關人員必須應對諸多挑戰，例如嚴格的監管要求、強制性的藥物安全監測、關於激素避孕的錯誤信息以及不同收入水平和地理位置人群之間持續存在的獲取途徑差異。相關行業主題包括口服避孕藥、荷爾蒙避孕藥、複方口服避孕藥、黃體素單藥療法、生殖健康、計劃生育、女性保健、避孕途徑和避孕依從性。

口服避孕藥領域的變革性變化

口服避孕藥市場格局正受到三大趨勢的重塑：更高的可及性、個人化的避孕照護以及數位化驅動的病人參與模式。醫療衛生系統和政策制定者日益將避孕定位為基本醫療服務，從而更好地將其與基層醫療、孕產婦保健、青少年保健和遠端醫療計畫相結合。在一些國家，監管程序和藥屋主導的配藥模式正在降低處方門檻，而公共衛生工作則繼續強調知情選擇和諮詢。製劑趨勢也在改變競爭格局，人們對低劑量雌激素製​​劑、新型孕激素、長效給藥週期以及適用於無法使用含雌激素產品的人群的單孕激素避孕藥的興趣持續高漲。患者的期望也隨之轉變，他們更傾向於便利、私密、副作用更少、月經週期可預測以及透過線上平台和零售藥局管道可靠地獲取藥物。然而，該領域面臨許多挑戰，例如用藥依從性問題、因副作用導致的停藥、某些複方製劑可能引發的靜脈血栓栓塞症風險，以及需要進行清晰的風險溝通。這些變化使得臨床教育、價格可負擔性、供應可靠性和以患者為中心的設計對於口服避孕藥的長期成功至關重要。

人工智慧對口服避孕藥的累積影響

人工智慧 (AI) 在口服避孕藥價值鏈中扮演著日益重要的角色，尤其是在臨床決策支援、病人參與、藥物安全監測、需求規劃和數位化用藥依從性專案方面。 AI 工具能夠幫助臨床醫生整理患者病歷、禁忌症、藥物交互作用、偏頭痛狀況、吸煙狀況、血壓狀況、哺乳狀況和血栓風險因素等信息，從而創建更規範的避孕諮詢流程。在數位健康領域，AI 驅動的提醒、互動式介面和個人化教育可以解決漏服藥物、突破性出血問題以及導致停藥的因素，並在出現預警訊號時及時提醒患者進行臨床隨訪。在安全監測方面，機器學習可用於從結構化和非結構化資料來源中識別不利事件訊號，從而提高應對力，但仍需要人工臨床監督和檢驗的報告流程。 AI 還可以透過檢測零售、公共部門和電子商務通路的需求模式變化來提高供應鏈的韌性。這些累積效應並不會取代實證臨床判斷，而是會促使避孕護理更加個人化、反應迅速且擴充性，前提是隱私、演算法公平性、監管合規性和與患者的透明溝通仍然是核心保障。

亞太地區、北美地區、拉丁美洲地區、歐洲地區以及中東和非洲地區的關鍵區域洞察

亞太地區的避孕需求高度多樣化。口服避孕藥的使用受各國計劃生育政策、都市化進程、藥局可近性、文化態度以及基層醫療水準的影響。中國、印度、日本、韓國、澳洲和東南亞國協的情況各不相同。在一些地區，長效避孕藥和公共部門提供的避孕服務受到重視，而都市區消費者擴大利用數位管道來獲取生殖健康資訊。在北美，完善的臨床基礎設施和廣泛的避孕意識，以及持續進行的關於生殖自主權和保險覆蓋範圍的政策討論，推動了人們對藥房服務、遠端醫療的需求。在拉丁美洲，荷爾蒙避孕藥的使用歷史悠久，巴西和墨西哥在區域需求中扮演著重要角色，但價格、農村地區的可及性以及公共部門持續提供的服務仍然是重要的障礙。在歐洲，完善的法律規範體系、較高的醫療素養以及處方箋避孕藥的廣泛可及性是其優勢所在。然而，報銷制度、醫護人員諮詢以及文化因素導致西歐、南歐、中歐和東歐在避孕藥具使用模式上有顯著差異。在中東，儘管都市區私人醫療機構的普及、女性教育水平的提高以及藥房網路的擴展有助於避孕藥具的獲取，但情況仍然複雜，社會規範和公共醫療服務不平衡限制了部分地區公開的避孕諮詢。非洲的避孕藥具獲取差距最為顯著。儘管口服避孕藥已被納入計劃生育項目，但由於庫存短缺、難以找到醫療服務提供者、資訊誤導、經濟負擔以及農村地區服務不均等因素，其使用受到限制。然而，社區健康舉措和捐助者支持的生殖健康計畫正在許多國家提高公眾意識和改善避孕藥具獲取途徑。

對東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約等關鍵組織的分析

在東南亞國協，由於人口結構年輕化、都市區零售藥局數量增加、數位醫療的普及以及公眾對計劃生育的重視，口服避孕藥的市場格局正在迅速變化，儘管各成員國的監管管道和報銷機制有所不同。在海灣合作理事會（GCC）國家，人們對私人醫療保健、女性健康服務以及透過藥局獲取避孕藥的需求日益成長，避孕諮詢受到文化期望、醫生指導和國家醫療保健現代化策略的影響。歐盟提供了一個高度監管且臨床結構化的環境，以產品品質、藥物安全監測、患者資訊標準和跨境監管一致性為中心，但報銷和獲取途徑仍然存在地域差異。金磚國家擁有先進的都市區醫療保健生態系統和大規模的未充分服務人口，共同反映了其廣泛而多樣的生殖健康需求。口服避孕藥的可近性受到公共工程、零售通路、本地生產能力和宣傳宣傳活動的影響。七國集團（G7）國家普遍擁有成熟的醫療衛生體系、強力的法律規範以及對激素避孕的高度認知，目前關注的重點包括：價格可承受性、公平獲取、遠端醫療、保護青少年隱私以及基於證據的風險和益處資訊。北約成員國與北美和歐洲的重疊區域顯著，在這些地區，藥品供應鏈的韌性、緊急準備以及基本藥物的持續供應正成為更關鍵的政策挑戰。這進一步凸顯了確保可靠採購、品質保證以及即使在醫療衛生系統中斷的情況下也能不間斷地獲得避孕藥具的必要性。

對主要口服避孕藥市場國家的關鍵洞察。

在美國，各州的政策差異顯著，但其共同特點是：擴大遠距遠端醫療避孕服務的覆蓋範圍、加強藥房參與，以及人們日益關注生殖自主權、避孕藥具的可負擔性和醫療覆蓋範圍。加拿大受惠於對公共衛生的高度重視，以及各省不斷加強降低避孕藥具的價格，儘管各州、各年齡層和農村地區的避孕藥可及性仍然存在差異。墨西哥和巴西是拉丁美洲的核心市場，在零售藥房網路和公共衛生計畫的支持下，口服避孕藥的認知度很高，但收入不平等和地區服務差異影響了避孕藥具的持續使用。在英國，避孕服務已透過基層醫療、性健康診所和藥局建立多年，儘管醫療系統面臨壓力，但仍在努力改善避孕藥具的可近性。德國、法國、義大利和西班牙實行結構化的歐洲醫療保健體系，醫生諮詢、保險報銷規則和國家處方規範影響口服避孕藥的使用。法國尤其重視年輕女性獲得避孕服務的途徑，而婦產科醫師主導的醫療服務在德國和西班牙發揮著至關重要的作用。義大利的情況則受到區域醫療保健差異和文化因素的影響。俄羅斯的情況更為複雜，避孕行為受到醫療服務提供者的可近性、公共衛生訊息、經濟負擔以及更廣泛的醫療保健系統動態的影響。中國的口服避孕藥現狀受到不斷變化的生殖政策、都市區消費者健康行為以及日益成長的數位醫療參與度的影響。同時，儘管印度存在著大規模的計劃生育需求，但都市區地區在避孕意識、諮詢品質和可及性方面仍存在顯著差異。日本和韓國擁有先進的醫療保健系統和嚴格的藥品監管，其口服避孕藥的普及歷來受到醫療規範、價格和病患意識的影響。澳洲擁有較高的避孕知識水平、強大的基層醫療參與度和不斷擴大的數位健康服務使用，其獲取途徑受處方過程、藥房供應情況以及患者對各種可逆避孕方法的偏好影響。

為口服避孕藥產業領導者提供的實用建議

產業領導者應優先考慮以病人為中心的准入策略，兼顧臨床可靠性、可負擔性、隱私性和便利性。加強與醫療服務提供者、藥局、遠端醫療平台和公共衛生計畫的合作，可以提高用藥的連續性，減少不必要的中斷。產品系列應反映多樣化的臨床需求，包括複方口服避孕藥、黃體素單藥療法、長週期製劑以及針對不同風險族群量身訂製的製劑。清晰、實證的教育至關重要，有助於消除人們對某些含雌激素產品相關罕見但嚴重風險的擔憂，例如副作用、出血模式改變、漏服、藥物交互作用和血栓性栓塞症。行業領導者應投資於文化敏感的溝通方式、多語言患者資源和數位化用藥依從性工具，以支持患者做出知情選擇，而不是取代醫療服務提供者的指導。應透過品質保證、需求可視性和針對重要生殖健康產品的緊急時應對計畫來增強供應鏈的韌性。監管機構和藥品安全監測團隊應保持嚴格的不利事件監測、透明的資訊揭露和快速回應機制。最後，負責任地使用人工智慧應著重於檢驗的決策支援、隱私保護、減少偏見，以及在諮詢品質、藥物依從性和患者滿意度方面取得可衡量的改進。

口服避孕藥分析的調查方法

本執行摘要基於二手研究方法，參考了公開可用的證據，包括國家衛生機構、國際公共衛生組織、監管指南、同行評審的醫學文獻、臨床實踐指南、藥物安全監測框架以及生殖健康政策方面的出版物。研究途徑調查方法強調對臨床、監管、人口統計和醫療保健可及性指標進行檢驗，以識別口服避孕藥使用、患者需求、安全考慮和區域可及性趨勢的一致模式。本分析不涉及市場規模、市場佔有率和預測，而是著重於對醫療保健基礎設施、政策方向、可及性障礙、製劑趨勢、數位醫療應用和病患行為進行定性和數據驅動的解讀。為確保分析的嚴謹性，區域、群體和國家層級的見解以說明形式呈現。所有結論均圍繞已驗證的行業促進因素和限制因素展開，包括避孕諮詢標準、基本藥物可及性、處方和配藥管道、可負擔性、用藥依從性、副作用管理和法律規範。

結論：建構一個更方便、以病人為中心的口服避孕藥生態系。

口服避孕藥作為一種可逆、易用且經臨床驗證的荷爾蒙避孕方法，在全球生殖健康領域繼續發揮至關重要的作用。該行業正朝著更個人化的照護、更廣泛的數位化管道、更完善的用藥依從性支持以及與基層醫療和藥房服務的更緊密整合方向發展。區域差異依然顯著，成熟的醫療體系專注於可負擔性、遠端醫療和監管安全，而新興和醫療服務不足的地區則優先考慮提高公眾意識、確保供應穩定、提供高品質的諮詢服務以及實現公平的獲取途徑。人工智慧（AI）可以增強決策支援、藥物安全監測、教育和供應鏈應對力，但其成功取決於透明度、臨床檢驗和隱私保護。對於口服避孕藥生態系中的所有相關人員，最大的機會在於建立信任、促進知情選擇、滿足患者的多樣化需求，並確保能夠不間斷地獲得安全、有效且循證的避孕方法。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 口服避孕藥市場：依產品類型分類

  • 複方口服避孕藥
  • 僅含黃體素的避孕藥

第8章 口服避孕藥市場：以劑型分類

  • 雙相
  • 單相型
  • 三相型

第9章 口服避孕藥市場：依劑量強度分類

  • 高劑量
  • 低劑量

第10章 口服避孕藥市場：依品牌分類

  • 品牌
  • 非專利的

第11章 口服避孕藥市場：依最終用戶分類

  • 醫院
  • 婦科診所
  • 居家照護環境
  • 計劃生育中心

第12章 口服避孕藥市場：依通路分類

  • 醫院藥房
  • 線上平台
  • 零售藥房

第13章 口服避孕藥市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 口服避孕藥市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 口服避孕藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc.
  • Amneal Pharmaceuticals LLC
  • Apotex Inc.
  • Aurobindo Pharma Limited
  • Bayer AG
  • Cipla Ltd.
  • CooperSurgical Inc.
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals
  • Johnson & Johnson
  • Lupin Pharmaceuticals
  • Mankind Pharma Ltd.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Piramal Enterprises Ltd.
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris Inc.
  • Zydus Lifesciences
Product Code: MRR-4676B64E6B2E

The Oral Contraceptive Pills Market is projected to grow by USD 31.77 billion at a CAGR of 7.09% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 19.66 billion
Estimated Year [2026] USD 21.05 billion
Forecast Year [2032] USD 31.77 billion
CAGR (%) 7.09%

Oral contraceptive pills remain one of the most widely used reversible contraceptive methods, supported by decades of clinical evidence, expanding reproductive health programs, and sustained demand for user-controlled family planning. The category includes combined oral contraceptives containing estrogen and progestin as well as progestin-only pills, each serving different clinical needs based on age, breastfeeding status, cardiovascular risk, migraine history, medication interactions, and patient preference. Demand is shaped by broader access to women's healthcare, digital health adoption, public-sector procurement, over-the-counter availability discussions, and rising awareness of menstrual cycle management, acne treatment, endometriosis-related symptom control, and polycystic ovary syndrome support. At the same time, industry participants must navigate strict regulatory requirements, pharmacovigilance obligations, misinformation around hormonal contraception, and persistent access gaps across income groups and geographies. Relevant industry themes include oral contraceptive pills, hormonal contraception, combined oral contraceptives, progestin-only pills, reproductive health, family planning, women's healthcare, contraceptive access, and contraception adherence.

Transformative Shifts in the Oral Contraceptive Pills Landscape

The oral contraceptive pills landscape is being reshaped by three major shifts: access expansion, personalization of contraceptive care, and digital-first patient engagement. Health systems and policymakers are increasingly treating contraception as an essential health service, which is improving integration with primary care, maternal health, adolescent health, and telehealth programs. In several countries, regulatory pathways and pharmacy-led dispensing models are reducing prescription barriers, while public health initiatives continue to emphasize informed choice and counseling. Formulation trends are also changing the competitive environment, with continued interest in lower-dose estrogen options, newer progestins, extended-cycle regimens, and progestin-only pills for populations who cannot use estrogen-containing products. Patient expectations are moving toward convenience, privacy, fewer side effects, predictable bleeding patterns, and reliable access through online platforms and retail pharmacy channels. However, the sector faces ongoing pressure from adherence challenges, discontinuation due to side effects, concerns about venous thromboembolism with some combined formulations, and the need for clear risk communication. These shifts are making clinical education, affordability, supply reliability, and patient-centered design central to long-term success in oral contraceptive pills.

Cumulative Impact of Artificial Intelligence on Oral Contraceptive Pills

Artificial intelligence is becoming increasingly relevant across the oral contraceptive pills value chain, particularly in clinical decision support, patient engagement, pharmacovigilance, demand planning, and digital adherence programs. AI-enabled tools can support clinicians by organizing patient history, contraindications, medication interactions, migraine status, smoking status, blood pressure considerations, breastfeeding status, and thrombotic risk factors into more consistent contraceptive counseling workflows. In digital health settings, AI-driven reminders, conversational interfaces, and personalized education can help address missed pills, breakthrough bleeding concerns, and discontinuation triggers while encouraging timely clinical follow-up when warning signs occur. In safety monitoring, machine learning can help identify adverse-event signals from structured and unstructured data sources, improving responsiveness to medication safety trends while still requiring human clinical oversight and validated reporting processes. AI can also improve supply-chain resilience by detecting changes in demand patterns across retail, public-sector, and e-commerce channels. The cumulative impact is not a replacement for evidence-based clinical judgment, but a shift toward more personalized, responsive, and scalable contraceptive care, provided that privacy, algorithmic fairness, regulatory compliance, and transparent patient communication remain core safeguards.

Key Regional Insights Across Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific is characterized by highly diverse contraceptive needs, with oral contraceptive pill use influenced by national family planning policies, urbanization, pharmacy access, cultural attitudes, and the strength of primary care systems. China, India, Japan, South Korea, Australia, and ASEAN countries show varied patterns, with some settings emphasizing long-acting and public-sector methods while urban consumers increasingly use digital channels for reproductive health information. North America demonstrates strong clinical infrastructure, broad contraceptive awareness, and growing interest in pharmacy access, telehealth prescribing, and over-the-counter availability, supported by ongoing policy debates around reproductive autonomy and insurance coverage. Latin America has a long history of hormonal contraceptive use, with Brazil and Mexico playing important roles in regional demand, although affordability, rural access, and public-sector continuity remain important barriers. Europe benefits from established regulatory oversight, high healthcare literacy, and wide availability of prescription contraceptives, while usage patterns differ substantially between Western, Southern, Central, and Eastern Europe due to reimbursement, provider counseling, and cultural factors. The Middle East reflects a mixed landscape in which urban private healthcare, rising women's education, and expanding pharmacy networks support access, while social norms and uneven public provision can limit open contraceptive counseling in some areas. Africa presents some of the most significant access disparities, with oral contraceptive pills included in family planning programs but constrained by stockouts, provider availability, misinformation, affordability, and rural service gaps; however, community health initiatives and donor-supported reproductive health programs continue to improve awareness and access in many countries.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN countries represent a fast-evolving oral contraceptive pills environment shaped by young demographics, urban retail pharmacy growth, expanding digital health adoption, and public family planning priorities, although regulatory pathways and reimbursement structures vary across member states. The GCC shows increasing demand for private healthcare, women's wellness services, and pharmacy-based access, with contraceptive counseling shaped by cultural expectations, physician guidance, and national health modernization strategies. The European Union provides a highly regulated and clinically structured environment where product quality, pharmacovigilance, patient information standards, and cross-border regulatory alignment are central, while reimbursement and access remain country-specific. BRICS countries collectively reflect large and heterogeneous reproductive health needs, combining advanced urban healthcare ecosystems with substantial underserved populations; oral contraceptive pill access is shaped by public-sector programs, retail availability, local manufacturing capacity, and education campaigns. G7 countries generally exhibit mature healthcare systems, strong regulatory oversight, and high awareness of hormonal contraception, with current attention focused on affordability, equitable access, telehealth, adolescent confidentiality, and evidence-based communication about risks and benefits. NATO countries overlap significantly with North America and Europe, where resilient pharmaceutical supply chains, emergency preparedness, and continuity of essential medicines have become more prominent policy priorities, reinforcing the need for reliable sourcing, quality assurance, and uninterrupted contraceptive access during health system disruptions.

Key Country Insights Across Major Oral Contraceptive Pill Markets

The United States is marked by significant policy variation across states, growing telehealth-based contraception access, pharmacy engagement, and heightened attention to reproductive autonomy, affordability, and insurance coverage. Canada benefits from a strong public health orientation and expanding provincial initiatives to improve contraceptive affordability, though access still differs by province, age group, and rural location. Mexico and Brazil are central Latin American markets where oral contraceptive pills are widely recognized, supported by retail pharmacy networks and public health programs, while income inequality and regional service gaps affect consistent use. The United Kingdom has long-established contraception services through primary care, sexual health clinics, and pharmacies, with ongoing efforts to improve access amid healthcare capacity pressures. Germany, France, Italy, and Spain operate within structured European healthcare systems where physician counseling, reimbursement rules, and national prescribing habits shape oral contraceptive pill use; France has placed particular emphasis on contraception access for younger women, while Germany and Spain show strong roles for gynecologist-led care, and Italy's patterns are influenced by regional healthcare variation and cultural factors. Russia presents a more complex environment, with contraceptive behaviors shaped by provider access, public health messaging, affordability, and broader healthcare system dynamics. China's oral contraceptive pill landscape is influenced by evolving reproductive policies, urban consumer health behavior, and growing digital health engagement, while India combines large family planning needs with significant variation in awareness, counseling quality, and access between urban and rural settings. Japan and South Korea have advanced healthcare systems and strong pharmaceutical regulation, yet oral contraceptive pill adoption has historically been influenced by medical norms, pricing, and patient awareness. Australia demonstrates high contraceptive literacy, strong primary care involvement, and growing use of digital health services, with access shaped by prescribing pathways, pharmacy availability, and patient preference for a range of reversible contraceptive options.

Actionable Recommendations for Oral Contraceptive Pills Industry Leaders

Industry leaders should prioritize patient-centered access strategies that combine clinical credibility, affordability, privacy, and convenience. Strengthening partnerships with healthcare providers, pharmacies, telehealth platforms, and public health programs can improve continuity of access and reduce avoidable discontinuation. Product portfolios should reflect diverse clinical needs, including combined oral contraceptives, progestin-only pills, extended-cycle options, and formulations appropriate for different risk profiles. Clear, evidence-based education is essential to address concerns about side effects, bleeding changes, missed pills, drug interactions, and rare but serious risks such as thromboembolic events associated with some estrogen-containing products. Leaders should invest in culturally relevant communication, multilingual patient materials, and digital adherence tools that support informed choice without replacing clinician guidance. Supply-chain resilience should be strengthened through quality assurance, demand visibility, and contingency planning for essential reproductive health products. Regulatory and pharmacovigilance teams should maintain rigorous adverse-event monitoring, transparent labeling, and rapid response processes. Finally, responsible use of AI should focus on validated decision support, privacy protection, bias reduction, and measurable improvements in counseling quality, adherence, and patient satisfaction.

Research Methodology for Oral Contraceptive Pills Analysis

This executive summary is developed using a secondary research approach grounded in publicly available, evidence-based sources such as national health agencies, global public health organizations, regulatory guidance, peer-reviewed medical literature, clinical practice recommendations, pharmacovigilance frameworks, and reproductive health policy publications. The methodology emphasizes triangulation across clinical, regulatory, demographic, and healthcare-access indicators to identify consistent patterns in oral contraceptive pill adoption, patient needs, safety considerations, and regional access dynamics. Analysis excludes market sizing, market share, and forecasting, focusing instead on qualitative and data-backed interpretation of healthcare infrastructure, policy direction, access barriers, formulation trends, digital health adoption, and patient behavior. Regional, group, and country insights are synthesized into narrative form to preserve readability while maintaining analytical rigor. All conclusions are framed around verified industry drivers and constraints, including contraceptive counseling standards, essential medicine access, prescription and pharmacy pathways, affordability, adherence, side-effect management, and regulatory oversight.

Conclusion: Building a More Accessible and Patient-Centered Oral Contraceptive Pills Ecosystem

Oral contraceptive pills continue to play a critical role in global reproductive health by offering a reversible, familiar, and clinically established method of hormonal contraception. The industry is moving toward more personalized care, broader digital access, improved adherence support, and stronger integration with primary healthcare and pharmacy services. Regional differences remain substantial, with mature healthcare systems focusing on affordability, telehealth, and regulatory safeguards, while emerging and underserved regions prioritize awareness, supply reliability, counseling quality, and equitable access. Artificial intelligence can enhance decision support, pharmacovigilance, education, and supply-chain responsiveness, but its success depends on transparency, clinical validation, and privacy protection. For stakeholders across the oral contraceptive pills ecosystem, the strongest opportunities lie in building trust, improving informed choice, supporting diverse patient needs, and ensuring uninterrupted access to safe, effective, and evidence-based contraception.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Oral Contraceptive Pills Market, by Product Type

  • 7.1. Introduction
  • 7.2. Combined Oral Contraceptives
  • 7.3. Progestin-Only Pills

8. Oral Contraceptive Pills Market, by Formulation

  • 8.1. Introduction
  • 8.2. Biphasic
  • 8.3. Monophasic
  • 8.4. Triphasic

9. Oral Contraceptive Pills Market, by Dosage Strength

  • 9.1. Introduction
  • 9.2. High Dose
  • 9.3. Low Dose

10. Oral Contraceptive Pills Market, by Brand

  • 10.1. Introduction
  • 10.2. Branded
  • 10.3. Generic

11. Oral Contraceptive Pills Market, by End User

  • 11.1. Introduction
  • 11.2. Hospitals
  • 11.3. Gynecology Clinics
  • 11.4. Homecare Settings
  • 11.5. Family Planning Centers

12. Oral Contraceptive Pills Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Hospital Pharmacy
  • 12.3. Online Platforms
  • 12.4. Retail Pharmacy

13. Oral Contraceptive Pills Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Oral Contraceptive Pills Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Oral Contraceptive Pills Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc.
  • 17.2. Amneal Pharmaceuticals LLC
  • 17.3. Apotex Inc.
  • 17.4. Aurobindo Pharma Limited
  • 17.5. Bayer AG
  • 17.6. Cipla Ltd.
  • 17.7. CooperSurgical Inc.
  • 17.8. Dr. Reddy's Laboratories Ltd.
  • 17.9. GlaxoSmithKline plc
  • 17.10. Glenmark Pharmaceuticals
  • 17.11. Johnson & Johnson
  • 17.12. Lupin Pharmaceuticals
  • 17.13. Mankind Pharma Ltd.
  • 17.14. Merck & Co. Inc.
  • 17.15. Novartis AG
  • 17.16. Pfizer Inc.
  • 17.17. Piramal Enterprises Ltd.
  • 17.18. Sanofi
  • 17.19. Sun Pharmaceutical Industries Ltd.
  • 17.20. Teva Pharmaceutical Industries Ltd.
  • 17.21. Torrent Pharmaceuticals Ltd.
  • 17.22. Viatris Inc.
  • 17.23. Zydus Lifesciences

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COMBINED ORAL CONTRACEPTIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMBINED ORAL CONTRACEPTIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COMBINED ORAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PROGESTIN-ONLY PILLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PROGESTIN-ONLY PILLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PROGESTIN-ONLY PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIPHASIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIPHASIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIPHASIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MONOPHASIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MONOPHASIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MONOPHASIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRIPHASIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TRIPHASIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRIPHASIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HIGH DOSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HIGH DOSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HIGH DOSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LOW DOSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LOW DOSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LOW DOSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BRANDED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRANDED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BRANDED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENERIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENERIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENERIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GYNECOLOGY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GYNECOLOGY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GYNECOLOGY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL FAMILY PLANNING CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL FAMILY PLANNING CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL FAMILY PLANNING CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ONLINE PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ONLINE PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ONLINE PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 111. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 112. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 113. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 132. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 133. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 134. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 139. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 140. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 141. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. CANADA ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. CANADA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. CANADA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 154. CANADA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 155. CANADA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 156. CANADA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. CANADA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. MEXICO ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. MEXICO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. MEXICO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 161. MEXICO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 162. MEXICO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 163. MEXICO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. MEXICO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. BRAZIL ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 166. BRAZIL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. BRAZIL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 168. BRAZIL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 169. BRAZIL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 170. BRAZIL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. BRAZIL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED KINGDOM ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED KINGDOM ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED KINGDOM ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED KINGDOM ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED KINGDOM ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED KINGDOM ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED KINGDOM ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. GERMANY ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. GERMANY ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. GERMANY ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 182. GERMANY ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 183. GERMANY ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 184. GERMANY ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. GERMANY ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. FRANCE ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. FRANCE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. FRANCE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 189. FRANCE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 190. FRANCE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 191. FRANCE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. FRANCE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. RUSSIA ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. RUSSIA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. RUSSIA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 196. RUSSIA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 197. RUSSIA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 198. RUSSIA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. RUSSIA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. ITALY ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 201. ITALY ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. ITALY ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 203. ITALY ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 204. ITALY ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 205. ITALY ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. ITALY ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. SPAIN ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. SPAIN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. SPAIN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 210. SPAIN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 211. SPAIN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 212. SPAIN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. SPAIN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. INDIA ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. INDIA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. INDIA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 224. INDIA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 225. INDIA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 226. INDIA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. INDIA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. JAPAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. JAPAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. JAPAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 231. JAPAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 232. JAPAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 233. JAPAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. JAPAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. AUSTRALIA ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. AUSTRALIA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. AUSTRALIA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 238. AUSTRALIA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 239. AUSTRALIA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 240. AUSTRALIA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. AUSTRALIA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. SOUTH KOREA ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. SOUTH KOREA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. SOUTH KOREA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 245. SOUTH KOREA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 246. SOUTH KOREA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 247. SOUTH KOREA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. SOUTH KOREA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 250. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025